Medicus Pharma Ltd (NASDAQ:MDCX) Short Interest Down 45.8% in June

Medicus Pharma Ltd (NASDAQ:MDCX) was the recipient of a significant drop in short interest in June. As of June 30th, there was short interest totaling 1,045,598 shares, a drop of 45.8% from the June 15th total of 1,928,591 shares. Based on an average daily volume of 2,653,037 shares, the days-to-cover ratio is presently 0.4 days. Currently, 2.0% of the shares of the stock are sold short.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of MDCX. Jane Street Group LLC purchased a new stake in shares of Medicus Pharma in the second quarter valued at $41,000. HRT Financial LP bought a new stake in shares of Medicus Pharma in the 4th quarter worth about $42,000. Osaic Holdings Inc. boosted its stake in shares of Medicus Pharma by 180.0% during the 2nd quarter. Osaic Holdings Inc. now owns 14,000 shares of the company’s stock worth $42,000 after purchasing an additional 9,000 shares during the period. Commonwealth Equity Services LLC boosted its stake in shares of Medicus Pharma by 161.8% during the 4th quarter. Commonwealth Equity Services LLC now owns 28,493 shares of the company’s stock worth $44,000 after purchasing an additional 17,611 shares during the period. Finally, May Hill Capital LLC grew its holdings in Medicus Pharma by 100.0% during the 4th quarter. May Hill Capital LLC now owns 35,622 shares of the company’s stock valued at $55,000 after purchasing an additional 17,811 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on MDCX. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Medicus Pharma in a research note on Wednesday, July 8th. Roth Capital initiated coverage on shares of Medicus Pharma in a research report on Tuesday, April 21st. They set a “buy” rating for the company. Finally, D. Boral Capital reissued a “buy” rating and issued a $9.00 price objective on shares of Medicus Pharma in a research note on Monday, April 20th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Medicus Pharma presently has an average rating of “Hold” and a consensus price target of $9.00.

Medicus Pharma Price Performance

Shares of NASDAQ:MDCX traded down $0.03 during trading on Friday, hitting $0.38. The company had a trading volume of 544,678 shares, compared to its average volume of 3,732,038. The stock has a market cap of $21.29 million, a price-to-earnings ratio of -0.14 and a beta of -0.05. Medicus Pharma has a one year low of $0.25 and a one year high of $3.35. The company has a fifty day simple moving average of $0.37 and a two-hundred day simple moving average of $0.70.

Medicus Pharma (NASDAQ:MDCX) last announced its earnings results on Thursday, May 14th. The company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.13). On average, equities research analysts anticipate that Medicus Pharma will post -0.51 earnings per share for the current year.

About Medicus Pharma

Medicus Pharma, Inc, traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer.

Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies.